136 related articles for article (PubMed ID: 8746763)
1. Acute MPTP treatment produces no changes in mitochondrial complex activities and indices of oxidative damage in the common marmoset ex vivo one week after exposure to the toxin.
Gerlach M; Götz M; Dirr A; Kupsch A; Janetzky B; Oertel W; Sautter J; Schwarz J; Reichmann H; Riederer P
Neurochem Int; 1996 Jan; 28(1):41-9. PubMed ID: 8746763
[TBL] [Abstract][Full Text] [Related]
2. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level.
Kupsch A; Sautter J; Schwarz J; Riederer P; Gerlach M; Oertel WH
Brain Res; 1996 Nov; 741(1-2):185-96. PubMed ID: 9001722
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
[TBL] [Abstract][Full Text] [Related]
4. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study.
Herkenham M; Little MD; Bankiewicz K; Yang SC; Markey SP; Johannessen JN
Neuroscience; 1991; 40(1):133-58. PubMed ID: 2052148
[TBL] [Abstract][Full Text] [Related]
5. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
6. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum.
Thomas B; Mohanakumar KP
J Pineal Res; 2004 Jan; 36(1):25-32. PubMed ID: 14675127
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset.
Gnanalingham KK; Milkowski NA; Smith LA; Hunter AJ; Jenner P; Marsden CD
Eur J Pharmacol; 1995 Apr; 277(2-3):235-41. PubMed ID: 7493614
[TBL] [Abstract][Full Text] [Related]
8. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide synthase inhibition and MPTP-induced toxicity in the common marmoset.
Mackenzie GM; Jackson MJ; Jenner P; Marsden CD
Synapse; 1997 Jul; 26(3):301-16. PubMed ID: 9183819
[TBL] [Abstract][Full Text] [Related]
10. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
[TBL] [Abstract][Full Text] [Related]
11. Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat.
Desole MS; Esposito G; Fresu L; Migheli R; Enrico P; Miele M; De Natale G; Miele E
Neurosci Lett; 1993 Oct; 161(2):121-3. PubMed ID: 7903798
[TBL] [Abstract][Full Text] [Related]
12. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment.
Smith TS; Trimmer PA; Khan SM; Tinklepaugh DL; Bennett JP
Brain Res; 1997 Aug; 765(2):189-97. PubMed ID: 9313891
[TBL] [Abstract][Full Text] [Related]
14. A model of chronic neurotoxicity: long-term retention of the neurotoxin 1-methyl-4-phenylpyridinium (MPP+) within catecholaminergic neurons.
Johannessen JN
Neurotoxicology; 1991; 12(2):285-302. PubMed ID: 1956587
[TBL] [Abstract][Full Text] [Related]
15. Toxic effects of MPP(+) and MPTP in PC12 cells independent of reactive oxygen species formation.
Fonck C; Baudry M
Brain Res; 2001 Jun; 905(1-2):199-206. PubMed ID: 11423095
[TBL] [Abstract][Full Text] [Related]
16. Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.
Battaglia G; Busceti CL; Cuomo L; Giorgi FS; Orzi F; De Blasi A; Nicoletti F; Ruggieri S; Fornai F
Neuropharmacology; 2002 Mar; 42(3):367-73. PubMed ID: 11897115
[TBL] [Abstract][Full Text] [Related]
17. Melatonin protects against MPTP/MPP+ -induced mitochondrial DNA oxidative damage in vivo and in vitro.
Chen LJ; Gao YQ; Li XJ; Shen DH; Sun FY
J Pineal Res; 2005 Aug; 39(1):34-42. PubMed ID: 15978055
[TBL] [Abstract][Full Text] [Related]
18. Increased dopamine turnover in the putamen after MPTP treatment in common marmosets.
Nomoto M; Iwata SI; Kaseda S; Fukuda T; Nakagawa S
Brain Res; 1997 Sep; 767(2):235-8. PubMed ID: 9367253
[TBL] [Abstract][Full Text] [Related]
19. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.
Albanese A; Granata R; Gregori B; Piccardi MP; Colosimo C; Tonali P
Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418
[TBL] [Abstract][Full Text] [Related]
20. Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide.
Cosi C; Marien M
Brain Res; 1998 Oct; 809(1):58-67. PubMed ID: 9795136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
